Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV001851984 | SCV002231742 | pathogenic | Early infantile epileptic encephalopathy with suppression bursts | 2023-09-15 | criteria provided, single submitter | clinical testing | This sequence change replaces aspartic acid, which is acidic and polar, with glycine, which is neutral and non-polar, at codon 212 of the KCNQ2 protein (p.Asp212Gly). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with KCNQ2-related conditions (PMID: 19344764). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 21794). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Asp212 amino acid residue in KCNQ2. Other variant(s) that disrupt this residue have been determined to be pathogenic (Invitae). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Experimental studies have shown that this missense change affects KCNQ2 function (PMID: 19344764). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt KCNQ2 protein function. |
Gene |
RCV000678087 | SCV000041648 | not provided | Seizures, benign familial neonatal, 1 | no assertion provided | literature only | BFNE (benign familial neonatal epilepsy) | |
Channelopathy- |
RCV003315301 | SCV004015069 | not provided | Complex neurodevelopmental disorder | no assertion provided | literature only |